Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Shares of biotech company 10x Genomics (NASDAQ:TXG ... Revenue declined by 10% year on year, reflecting ongoing weakness in demand, particularly in instrument sales, though consumables performed ...

Get access to 10+ additional ProTips and comprehensive valuation metrics with InvestingPro's detailed research report. In other recent news, 10X Genomics announced preliminary fourth-quarter sales ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT ... Plate-based workflows for Chromium GEM-X Flex: The company announced plans for plate-based GEM-X Flex ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (LSE ... of all funds dedicated to 0A88 is 0.10%, an increase of 21.48%. Total shares owned ...

Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq ... 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time. Interested parties may access a live webcast ...